1. Bannister, A.J., Cook, A., and Kouzarides, T. (1991) In vitro DNA binding activity of Fos/Jun and BZLF1 but not C/EBP is affected by redox changes. Oncogene 6: 1243–1250.
2. Bass, D.A., Parce, J.W., Dechatelet, L.R., Szedja, P., Seeds, M.C., and Thomas, M. (1983) Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J. Immunol. 130: 1910–1917.
3. Bierer, B.E., and Nathan, D.G. (1990) The effect of desferrithiocin, an oral iron chelator, on T-cell function. Blood 76: 2052–2059.
4. Blatt, J., Taylor, S.R., and Kontoghiorghes, G.J. (1989) Comparison of activity of deferoxamine with that of oral iron chelators against human neuroblastoma cell lines. Cancer Res. 49: 2925–2927.
5. Carotenuto, P., Pontesilli, O., Cambier, J.C., and Hayward, A.R. (1986) Desferoxamine blocks IL 2 receptor expression on human T lymphocytes. J. Immunol. 136: 2342–2347.